What is the intrinsic value of SXTC?
As of 2025-05-17, the Intrinsic Value of China SXT Pharmaceuticals Inc (SXTC) is
2.11 USD. This SXTC valuation is based on the model Peter Lynch Fair Value.
With the current market price of 1.20 USD, the upside of China SXT Pharmaceuticals Inc is
75.44%.
Is SXTC undervalued or overvalued?
Based on its market price of 1.20 USD and our intrinsic valuation, China SXT Pharmaceuticals Inc (SXTC) is undervalued by 75.44%.
SXTC Intrinsic Value - Valuation Summary
|
Range |
Selected |
Upside |
| a |
| DCF (Growth 5y) |
(30.81) - (1.71) |
(3.67) |
-406.0% |
| DCF (Growth 10y) |
(1.58) - (25.78) |
(3.21) |
-367.8% |
| DCF (EBITDA 5y) |
(0.85) - (1.74) |
(1,234.50) |
-123450.0% |
| DCF (EBITDA 10y) |
(0.92) - (1.77) |
(1,234.50) |
-123450.0% |
| Fair Value |
2.11 - 2.11 |
2.11 |
75.44% |
| P/E |
3.93 - 6.67 |
5.14 |
328.5% |
| EV/EBITDA |
3.20 - 8.71 |
5.62 |
368.3% |
| EPV |
(1.99) - (2.75) |
(2.37) |
-297.5% |
| DDM - Stable |
4.73 - 62.18 |
33.45 |
2687.8% |
| DDM - Multi |
(2.23) - (22.55) |
(4.04) |
-436.5% |
SXTC Intrinsic Value - Key Valuation Metrics
| Market Cap (mil) |
26.10 |
| Beta |
1.39 |
| Outstanding shares (mil) |
21.75 |
| Enterprise Value (mil) |
9.80 |
| Market risk premium |
4.60% |
| Cost of Equity |
6.16% |
| Cost of Debt |
4.25% |
| WACC |
6.00% |